Comparative Pharmacology
Head-to-head clinical analysis: CHLORZOXAZONE versus DANTROLENE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORZOXAZONE versus DANTROLENE SODIUM.
CHLORZOXAZONE vs DANTROLENE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Dantrolene sodium dissociates the excitation-contraction coupling in skeletal muscle by inhibiting calcium release from the sarcoplasmic reticulum via ryanodine receptor blockade.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
25 mg orally once daily for 7 days; then 25 mg three times daily for 7 days; then 50 mg three times daily for 7 days; then 100 mg three times daily. Maximum daily dose: 400 mg. For malignant hyperthermia: 1 mg/kg intravenously, may repeat up to cumulative dose of 10 mg/kg.
None Documented
None Documented
Clinical Note
moderateChlorzoxazone + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluticasone propionate."
Clinical Note
moderateChlorzoxazone + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Chlorzoxazone."
Clinical Note
moderateChlorzoxazone + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Chlorzoxazone."
Clinical Note
moderateChlorzoxazone + Sulfisoxazole
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Terminal elimination half-life is approximately 8-10 hours in adults; may be prolonged to 12-15 hours in elderly or patients with hepatic impairment. Steady-state achieved in 3-4 days.
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
Primarily hepatic metabolism; approximately 25% excreted in urine as metabolites, 45-50% in feces via bile; less than 1% unchanged in urine.
Category C
Category A/B
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The metabolism of Sulfisoxazole can be decreased when combined with Chlorzoxazone."